Loading
Economic and Financial Impacts of Cancer / Breast Cancer Treatment Studies · Journal article
BMC Health Services Research · August 10, 2026
Reinforces what was already believed, rather than introducing something new.
This retrospective cost-effectiveness analysis of 165 Turkish patients with HR(+) HER2(−) early-stage breast cancer demonstrates that Oncotype DX Recurrence Score–guided treatment decisions reduce unnecessary chemotherapy and achieve cost-effectiveness gains of at least $1938 per QALY compared to clinicopathological assessment alone, when applied using TAILORx criteria. The study confirms that 41 of 92 chemotherapy-scheduled patients were reclassified as genomically low-risk and spared chemotherapy, supporting the clinical utility of RS-guided de-escalation.
Retrospective cost-effectiveness analysis of a prospective cohort. 165 HR(+) HER2(−) early-stage breast cancer patients from a Turkish centre, originally enrolled in a prospective clinical study; inclusion and exclusion criteria not specified.. Intervention: Oncotype DX Recurrence Score (ODX RS®) testing; adjuvant chemotherapy decision based on RS and TAILORx criteria.. Compared with: Clinicopathological assessment alone (NSABP-20 criteria); endocrine therapy alone vs chemotherapy + endocrine therapy.. n = 165. Turkey (single centre).
Among 92 patients scheduled for chemotherapy, 41 (44.6%) were genomically low-risk and omitted from chemotherapy based on RS results Using updated TAILORx criteria, 18 patients (~20%) would have received unnecessary chemotherapy under the prior NSABP-20 criteria alone ODX RS was at least $1938 more cost-effective than clinicopathological assessment alone (0.68 QALYs gained)
Cost-effectiveness model parameters (work loss, QoL penalty) not fully detailed; ICER based partly on assumptions about chemotherapy toxicity.
Clinicians in settings where Oncotype DX is available can use this evidence to support RS-guided de-escalation of chemotherapy in HR(+) HER2(−) patients, consistent with TAILORx; cost-effectiveness analysis is specific to Turkish healthcare economics and may not generalise internationally. The finding that ~20% of patients receive unnecessary chemotherapy under older criteria reinforces the value of genomic testing, but the small number of recurrence events limits confidence in long-term safety of de-escalation in this cohort.
A retrospective cost-effectiveness analysis in a single-centre Turkish cohort that confirms ODX RS reduces unnecessary chemotherapy and improves cost-effectiveness compared to clinicopathological assessment alone, consistent with TAILORx trial findings but without new primary efficacy data.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians in settings where Oncotype DX is available can use this evidence to support RS-guided de-escalation of chemotherapy in HR(+) HER2(−) patients, consistent with TAILORx; cost-effectiveness analysis is specific to Turkish healthcare economics and may not generalise internationally. The finding that ~20% of patients receive unnecessary chemotherapy under older criteria reinforces the value of genomic testing, but the small number of recurrence events limits confidence in long-term safety of de-escalation in this cohort.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
The aim of this study is to re-evaluate the decision of adjuvant chemotherapy according to TAILORx trial in our patients included in the prospective clinical study based on NSABP-20 criteria, and to recalculate the cost-effectiveness of ODX RS. Patients were analyzed for cost-effectiveness in the chemotherapy + endocrine therapy or endocrine therapy. The cost-effectiveness analyses of treatment before and after the ODX RS ® result were compared according to Tailor X. The deterioration in quality of life during chemotherapy was calculated based on the time the patient was away from daily activities, 6 months of work loss in 1 year and the cost of chemotherapy. ICER (ICER: Incremental Cost-Effectiveness Ratio) was calculated for cost-effectiveness. During a median follow-up period of 108.4 months (range 15.8–111), in 11 (6.7%) patients metastases were detected. Three patients (1.8%) died due to breast cancer. Among 92 patients who were scheduled for chemotherapy (CT) before the RS ® results were available, 41 were genomically low-risk and based on this findings were omitted from chemotherapy. According to the first study in which the chemotherapy decision was based on NSABP-20 18 patients (~ 20%) received unnecessary chemotherapy with the updated Tailor X criteria. Compared to a purely clinico-pathological assesment, a treatment based on ODX RS ® was found to be at least $1938 more cost-effective (0.68 QALYs). In conclusion, the Oncotype DX Recurrence Score (ODX RS ® ) test in Turkey was found to be cost-effective in HR(+) HER2(-) patients according to the updated TAILORx data for adjuvant chemotherapy decisions. Not applicable.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.